I'll go with published studies like the following:
- Baar, M. P., Brandt, R. M. C., Putavet, D. A., Klein, J. D. D., Derks, K. W. J., Bourgeois, B. R. M., ... & de Keizer, P. L. J. (2017). Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 169(1), 132–147.e16.
- Wu, Y., Shen, S., Shi, Y., Tian, N., Zhou, Y., & Zhang, X. (2022). Senolytics: Eliminating senescent cells and alleviating intervertebral disc degeneration. Frontiers in Bioengineering and Biotechnology, 10, Article 823945. Frontiers | Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration
- Zhang, C., Xie, Y., Chen, H., Lv, L., Yao, J., Zhang, M., ... & Liu, G. (2020). FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging, 12(2), 1272–1280. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice | Aging
FOXO4-DRI is susceptible to degradation by proteases present in tissues such as muscle or fat. It is administered intraperitoneally or intravenously to increase the absorption rates, increase bioavailability and to decrease immunological response compared to intramuscular or subcutaneous administration routes.
For a 70kg human, the IP or IV dosage would be ~30mg every third day assuming the same dosing schedule used in animal studies. IM or SC dosages could be expected to be anywhere from 25% to 100% higher due to protease degradation alone. The real problem though comes from the immune response as the FOXO4-DRI would most likely be identified as a foreign body and specific antibodies produced to neutralize its presence. I believe Ghoul has discussed the issue of immune response and GLP-1RAs, and this is in line with his reasoning as well.
I went down this rabbit hole a while back. I'm not comfortable with IV or IP administration at this time and the combination of cost and potential immunological risks of a UGL product makes SC or IM untenable currently. I do look forward to more research.